CALR and autoimmune disease: The efficacy of filgotinib in a group consisting of patients with pSS and sSS accompanied by other autoimmune diseases, such as RA or systemic lupus erythematosus, DM, and positive anti-Ro/SS-A or anti-La/SS-B antibodies, was explored in a randomized, double-blind, placebo-controlled study.